Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
26 September, 2017 23:53 IST
Jubilant Life' arm to negotiate potential acquisition of speciality biz in USA
Source: IRIS | 21 Mar, 2017, 10.16AM
Comments  |  Post Comment

Jubilant Life Sciences' material wholly owned subsidiary in Singapore, Jubilant Pharma (JPL) has received an approval to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The board of directors of JPL at its meeting has approved for the same.

The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materializes.

Shares of the company gained Rs 7.65, or 0.97%, to trade at Rs 793.00. The total volume of shares traded was 81,616 at the BSE (10.08 a.m., Tuesday).



Jubilant Life Sciences Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
GE Shipping takes delivery of secondhand medium gas carrier - 26-Sep-2017 11:37
Infosys accelerates private cloud adoption with OpenStack solution - 26-Sep-2017 10:09
SBI revises service charges on maintaining monthly average balance - 26-Sep-2017 10:04
Vivimed Labs inks pacts to facilitate investment of USD 42.5 mn - 26-Sep-2017 09:56
Gayatri Projects' JV bags order worth Rs 14.83 bn - 25-Sep-2017 15:15
Lupin receives USFDA approval for generic Clobex lotion - 25-Sep-2017 14:53
Suven Life Sciences secures product patents in India, Japan - 25-Sep-2017 12:10
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer